2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Head & Neck
2
Genitourinary
2
Endocrine
2
CNS
2
Thoracic
1
NET
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
5
Sarcoma
4
Neoplasms
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Glioma
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Uveal Melanoma
1
Thrombocytosis
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Noonan Syndrome 6
1
Interventions
Cisplatin
19
Docetaxel
17
Cetuximab
12
Carboplatin
12
Radiotherapy
11
Magnetic Resonance Spectroscopy
10
Biopsy
10
pembrolizumab
9
Paclitaxel
9
Radiotherapy, Intensity-Modulated
8
Immunohistochemistry
8
Erlotinib Hydrochloride
8
Trastuzumab
7
Gemcitabine
7
Chemotherapy, Adjuvant
7
Specimen Handling
6
Radiotherapy, Conformal
5
Radiosurgery
5
Gene Expression Profiling
5
Fluorodeoxyglucose F18
5
Capecitabine
5
Vorinostat
4
Taxes
4
Sorafenib
4
Polymerase Chain Reaction
4
Nivolumab
4
Bevacizumab
4
trastuzumab deruxtecan
3
sargramostim
3
bicalutamide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
entrectinib
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA